Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBIT (2016 - 2025)

Historic EBIT for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to -$1.9 million.

  • BioCorRx's EBIT fell 1722.37% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year decrease of 1248.25%. This contributed to the annual value of -$5.1 million for FY2024, which is 3523.71% down from last year.
  • According to the latest figures from Q3 2025, BioCorRx's EBIT is -$1.9 million, which was down 1722.37% from -$1.4 million recorded in Q2 2025.
  • In the past 5 years, BioCorRx's EBIT registered a high of -$822712.0 during Q4 2023, and its lowest value of -$1.9 million during Q3 2025.
  • For the 5-year period, BioCorRx's EBIT averaged around -$1.2 million, with its median value being -$1.1 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first surged by 5527.81% in 2021, then tumbled by 7255.18% in 2024.
  • BioCorRx's EBIT (Quarter) stood at -$1.3 million in 2021, then grew by 11.03% to -$1.2 million in 2022, then surged by 30.62% to -$822712.0 in 2023, then crashed by 36.71% to -$1.1 million in 2024, then crashed by 72.98% to -$1.9 million in 2025.
  • Its EBIT was -$1.9 million in Q3 2025, compared to -$1.4 million in Q2 2025 and -$937946.0 in Q1 2025.